《現(xiàn)代脂質(zhì)三聯(lián)治療》ppt課件-全文預(yù)覽
【正文】 ramingham Heart Study CAD risk as a function of LDLC and HDLC in men (50 to 70 y) CASTELLI WP. Am J Cardiol 1998。現(xiàn)代脂質(zhì)三聯(lián)治療 Introduction Part I Efficacy The Power to Reach Target Key Factor: + Differentiators: LDL Reduction TG HDL LDL/HDL Ratio The Lipid Triad The LDL/HDL Ratio Our Strength, Our Story!! Clear positioning for Lipobay A new perception of efficacy Differentiation to Atorvastatin Fit with our product profile LDL HDL Additional risk factor, especially in diabetics The Lipid Triad Overview TG The Lipid Triad The Ratio The Lipid Triad and Strategic Rationale Part II ? No scientific evidence ? Evidence contradicting this statement ? A marketing hypothesis to build their LDL story ? Creating the perception of the statin with the strongest efficacy It’s logical It’s measurable It’s practicable The Lipid Triad The GP’s Perspective Supporting Data from Landmark Studies Part III 12 10 8 6 4 2 0 % Mortality Placebo Q1 Q2 Q3 Q4 (low HDLincrease) (high HDLincrease) 4S Study CAD Mortality per Quartiles of Increases in HDLCholesterol KJEKSHUS J amp。 LDLC showed a 22% reduction in bined fatal and nonfatal MI HDL Cholesterol as Risk Factor for CHD LRC CPPT (Placebo) MRFIT (usual care) Incidence rate of CHD Incidence rate of CHD 12 10 8 6 4 2 0 100 130 160 190 GORDON DJ et al. Circulation 1989。 101: 477484 LDL/HDL Ratio as Therapeutic Success Placebo Statin 24 116 31 245 0 50 100 150 200 250 300 = 5 5 LDL / HDL Ratio Triglycerides 200 mg/dl Triglycerides = 200 mg/dl CAD cases per 1,000 subjects in 6 years ASSMANN G and SCHULTE H。 MMV Medizin Verlag, 1993: 43 5 High CHD risk Medium CHD risk Low CHD risk 35 3 PROCAM Heart Study Mean values for developing atherosclerotic CHD within 6 years Variable CHD Development No CHD Development (n = 186) (n = 4221) TC (mg/dl) HDLC (mg/dl) LDLC (mg/dl)
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1